Wegovy semaglutide tablets.
Michael Siluk | Common Photos Group | Getty Photos
Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy weight problems drug merchandise that goals to make sure cash-paying sufferers see decrease, “predictable” month-to-month costs.
Eligible sufferers can select between three-, six- or 12-month subscriptions for the Wegovy injection or the 2 highest doses of the newly launched tablet beneath the identical model title. Longer plans supply decrease month-to-month pricing, and the corporate expects individuals to avoid wasting as much as $1,200 a yr on the injection and as a lot as $600 a yr on the tablet, relative to paying for his or her particular person dose every month, in keeping with a Novo launch.
Sufferers can anticipate to pay flat month-to-month costs, even when they transfer to completely different doses, the corporate stated. The subscription program can be obtainable beginning Tuesday on a number of of Novo’s telehealth companions, together with Ro, WeightWatchers and LifeMD. Sesame, Hims & Hers and extra are anticipated to be added quickly.
The primary-of-its-kind providing is “a possibility to assist sufferers not solely begin however keep on remedy and assist them handle the ups and downs of a number of the pricing issues,” regardless if they’re beginning remedy or are presently taking the drug, stated Ed Cinca, Novo’s head of selling and affected person options.
Lack of ability to remain on GLP-1s is a longstanding difficulty attributable to elements equivalent to issue accessing the medicine and gastrointestinal unwanted side effects, with one 2025 research estimating that round 65% of sufferers with weight problems cease remedy inside a yr.
Wegovy subscription costs and estimated financial savings
Injection subscription plans (0.25, 0.5, 1.7 and a pair of.4 milligram doses)
- 3-month: $329 monthly, financial savings of $240 per yr
- 6-month: $299 monthly, financial savings of $600 per yr
- 12-month: $249 monthly, financial savings of $1,200 per yr
Capsule subscription plans (9 and 25 milligram doses)
- 3-month: $289 monthly, financial savings of $120 per yr
- 6-month: $269 monthly, financial savings of $360 per yr
- 12-month: $249 monthly, financial savings of $600 per yr
The brand new program additionally comes as Novo’s tablet, which has seen explosive uptake since its U.S. launch in January, is about to face recent competitors from an upcoming oral GLP-1 from chief rival Eli Lilly later this yr. Lilly is presently the dominant participant within the branded GLP-1 market within the U.S., with an estimated 60% share, whereas Novo has about 39%.
The Wegovy tablet has largely been reaching individuals who did not beforehand take GLP-1 injections, making it essential for Novo to seize as many new sufferers as it may possibly earlier than a competitor arrives.
As Novo Nordisk’s subscription plans launch, cash-paying sufferers can nonetheless pay $149 monthly for the decrease doses of the tablet, that are 1.5 and 4 milligrams. However beginning in September, the 4-milligram dose will value $199 monthly. In the meantime, the not too long ago accredited 7.2-milligram dose of Wegovy can be added to the subscription program at a later date.
Cinca emphasised that sufferers can choose out of the subscription whereas it is lively in the event that they not want to enroll.
“We wish to assist sufferers establish a path that may assist them really feel comfy about treating [obesity] in the long run,” he added.
Cinca stated Novo will not be but providing this system on its NovoCare direct-to-consumer pharmacy, however added that there is “a possibility to guage how this goes after which construct it out” by means of that platform over time.